<?xml version="1.0" encoding="UTF-8"?>
<ref id="B25-ijerph-17-04951">
 <label>25.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Rockstroh</surname>
    <given-names>J.K.</given-names>
   </name>
   <name>
    <surname>Orkin</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Viani</surname>
    <given-names>R.M.</given-names>
   </name>
   <name>
    <surname>Wyles</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Luetkemeyer</surname>
    <given-names>A.F.</given-names>
   </name>
   <name>
    <surname>Lazzarin</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Lazzarin</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Soto-Malave</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Nelson</surname>
    <given-names>M.R.</given-names>
   </name>
   <name>
    <surname>Bhagani</surname>
    <given-names>S.R.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Safety and efficacy of ombitasvir, paritaprevir with ritonavir Â± dasabuvir with or without ribavirin in patients with human immunodeficiency virus-1 and hepatitis C virus genotype 1 or genotype 4 coinfection: TURQUOISE-I Part 2</article-title>
  <source>Open Forum Infect. Dis.</source>
  <year>2017</year>
  <volume>4</volume>
  <fpage>ofx154</fpage>
  <pub-id pub-id-type="doi">10.1093/ofid/ofx154</pub-id>
  <pub-id pub-id-type="pmid">28948180</pub-id>
 </element-citation>
</ref>
